23andMe CEO on the future of genomics The Human Genome Task.

23andMe CEO on the future of genomics The Human Genome Task, completed in 2003, changed science and medicine single-handedly. Because of DNA sequencing technology we are learning even more about human health than ever before, gaining insight into complex illnesses and unlocking mysteries about human being ancestry and evolution http://l-e-v-i-t-r-a.com/ . Anne Wojcicki, cEO and founder of 23andMe, is among the pioneers in the booming genomics industry. Wojcicki’s company was the first ever to bring genetic screening to the home frontier with her direct-to-consumer DNA testing kits. While 23andMe has come across its fair share of challenges, the business seeks to empower the public and change just how we think about our health and genetic makeup.

‘While the general public increasingly sees marijuana seeing that a harmless medication, its use does involve some risks of adverse outcomes, and as the rate of marijuana users in the populace boosts, the risk of these consequences increases as well,’ said business lead researcher Deborah Hasin, a professor of epidemiology in Columbia University in New York City. Health care professionals, policy manufacturers and the public must deal with the findings in a balanced method, she added. Attitudes and Laws and regulations about marijuana are changing, Hasin said.